The price of the cholesterol drug Repatha has been cut by 60 percent, from about $14,000 to $5,850 per year, maker Amgen Inc. said Wednesday.

Latest Cholesterol News

The price reduction will be especially helpful for Medicare beneficiaries, according to Amgen CEO Robert Bradway. Many now have out-of-pocket costs of $370 per month, but that will fall to $25 to $150 per month, depending on their specific prescription plan, the Associated Press reported.

In May, rivals Sanofi and Regeneron significantly reduced what they charge prescription plans, but not the list price, for their similar cholesterol medication, Praluent.

Repatha and Praluent are self-injected drugs prescribed to patients who have high cholesterol but either can’t tolerate the side effects of cholesterol drugs called statins or haven’t had good results with statins, the AP reported.

High cholesterol increases the risk of heart attack and stroke.

Because generic statin pills cost pennies a day, prescription plans have limited the number of patients approved for Repatha or Praluent, the AP reported.

Copyright © 2018 HealthDay. All rights reserved.